MicRhoGAM Shortage Update: What Patients Need to Know in 2026

If your provider recently prescribed MicRhoGAM and your pharmacist told you it was unavailable or on backorder, you are experiencing the downstream effects of one of the most consequential biologic drug shortages of recent years. The U.S. supply of Rho(D) immune globulin — the class of medications to which MicRhoGAM belongs — has been disrupted since late 2023, with ongoing impacts felt across retail pharmacies in 2026.

Here is everything you need to know about the status of the MicRhoGAM shortage, what has been done to address it, and how to protect your health in the meantime.

How the Shortage Started

The Rho(D) immune globulin shortage was first announced in December 2023 and was officially reported to the public in March 2024 by the FDA, the American Society of Health-System Pharmacists (ASHP), and the Association for the Advancement of Blood & Biotherapies (AABB). The shortage was caused by two overlapping problems:

Anti-D plasma supply constraints: RhIg is manufactured from the plasma of donors with high levels of anti-D antibodies — a rare and specialized donor pool. Supply constraints in the anti-D plasma market created a raw material bottleneck.

Manufacturing deviations at Kedrion Biopharma: Kedrion Biopharma, the manufacturer of both RhoGAM and MicRhoGAM, encountered manufacturing deviations and plant maintenance requirements that slowed production at a critical time.

Initially the shortage affected just one manufacturer, but it quickly expanded to impact multiple RhIg producers as demand outpaced total available supply. The shortage has been particularly challenging because MicRhoGAM and RhoGAM are the most widely recognized RhIg brands — and many patients weren't aware that clinically equivalent alternatives existed.

Timeline of Key Events

December 2023: Shortage first announced internally within healthcare systems.

March 2024: FDA, ASHP, and AABB formally announce a major U.S. shortage of RhIg products including RhoGAM/MicRhoGAM.

Mid-2024: ACOG issues a Practice Advisory with shortage management and conservation strategies for providers.

August 2024: The WinRho SDF shortage (Kamada Ltd.) is resolved, easing pressure on that product — though the Kedrion RhoGAM/MicRhoGAM shortage continues.

Late 2024–2025: Kedrion brings manufacturing processes in-house, expands KEDPLASMA donation centers. FFF Enterprises announces allocation on RhoGAM lifted — product again available for order. However, localized retail shortages continue.

2026: Overall supply has improved but availability remains uneven. Some pharmacies have consistent stock; others experience periodic gaps. Patients in rural areas and those relying on large chain pharmacies are most likely to encounter shortages.

Who Is Most Affected?

MicRhoGAM is specifically used for Rh-negative patients experiencing first-trimester pregnancy events. Patients most affected by the shortage include:

Rh-negative individuals who have experienced a miscarriage, induced abortion, or ectopic pregnancy at 12 weeks or less of gestation

Patients presenting to emergency departments or urgent care after early pregnancy loss

Patients in communities with limited access to large hospital systems (which tend to have more reliable stock)

What to Do If You Can't Find MicRhoGAM

Contact your provider immediately — do not wait. They may have in-office stock or can direct you to a hospital pharmacy.

Ask for a brand-flexible prescription that allows substitution with HyperRHO S/D Mini-Dose, Rhophylac, or WinRho SDF.

Use medfinder to quickly identify which pharmacies near you have the medication in stock without calling each one manually.

Remember: the 72-hour window is critical. If you cannot find RhIg within 72 hours, go to an emergency department.

To find available stock near you, use medfinder. For a full breakdown of your options, see our guide to MicRhoGAM alternatives.